Evidence map›Paper›PMID 26155943›Full record

ArticleOncotarget2015

Requirement of novel amino acid fragments of orphan nuclear receptor TR3/Nur77 for its functions in angiogenesis.

Yan Li, Pierre M Bourbon, Marianne A Grant, Jin Peng, Taiyang Ye, Dezheng Zhao, Huiyan Zeng

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Yan LiCenter for Vascular Biology Research and Division of Molecular and Vascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Pierre M BourbonDepartment of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Marianne A GrantCenter for Vascular Biology Research and Division of Molecular and Vascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Jin PengCenter for Vascular Biology Research and Division of Molecular and Vascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Taiyang YeCenter for Vascular Biology Research and Division of Molecular and Vascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Dezheng ZhaoCenter for Vascular Biology Research and Division of Molecular and Vascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Huiyan ZengCenter for Vascular Biology Research and Division of Molecular and Vascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Beth Israel Deaconess Medical Center · USHarvard University · USCenter for Vascular Biology Research · USRenji Hospital · CN

Funding

Structure-Function and Mechanistic Regulation of FOXO/DNA ComplexesR01HL086766 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GRANT, MARIANNE AMANDA · 2011 to 2015
$2.1M
Regulation of colitis by orphan nuclear receptor Nur77R01DK095873 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ZHAO, DEZHENG · 2013 to 2017
$1.9M
Orphan Nuclear Receptor TR3 in tumor angiogenesis and associated microvessel permR01CA133235 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ZENG, HUIYAN · 2009 to 2013
$1.7M
Orphan nuclear receptor Nur77 and intestinal inflammmationR21DK080970 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ZHAO, DEZHENG · 2009 to 2010
$468k
NCI NIH HHS R01 CA133235NCI NIH HHS R01CA133235NHLBI NIH HHS R01 HL086766NHLBI NIH HHS R01HL086766NIDDK NIH HHS R01 DK095873NIDDK NIH HHS R01DK095873NIDDK NIH HHS R21 DK080970NIDDK NIH HHS R21DK080970
6 · The paper itself

Abstract

Pathological angiogenesis is a hallmark of many diseases. We demonstrated that TR3/Nur77 is an excellent target for pro-angiogenesis and anti-angiogenesis therapies. Here, we report that TR3 transcriptionally regulates endothelial cell migration, permeability and the formation of actin stress fibers that is independent of RhoA GTPase. 1) Amino acid residues 344-GRR-346 and de-phosphorylation of amino acid residue serine 351 in the DNA binding domain, and 2) phosphorylation of amino acid residues in the 41-61 amino acid fragment of the transactivation domain, of TR3 are required for its induction of the formation of actin stress fibers, cell proliferation, migration and permeability. The 41-61 amino acid fragment contains one of the three potential protein interaction motifs in the transactivation domain of TR3, predicted by computational modeling and analysis. These studies further our understanding of the molecular mechanism, by which TR3 regulates angiogenesis, identify novel therapeutic targeted sites of TR3, and set the foundation for the development of high-throughput screening assays to identify compounds targeting TR3/Nur77 for pro-angiogenesis and anti-angiogenesis therapies.

Indexed as

Neovascularization, PathologicAmino Acid MotifsAmino AcidsAngiogenesis InhibitorsBinding SitesCell Membrane PermeabilityCell MovementCell ProliferationComputer SimulationEndothelial CellsHigh-Throughput Screening AssaysHumansHuman Umbilical Vein Endothelial CellsMicroscopy, FluorescenceMutationNuclear Receptor Subfamily 4, Group A, Member 1Amino AcidsAngiogenesis InhibitorsNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1rhoA GTP-Binding ProteinRHOA protein, humanVascular Endothelial Growth Factor Aactin stress fibersmigrationpermeabilityproliferationprotein binding site

Identifiers

PMID26155943
PMCPMC4695184
OpenAlexW1647457634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.